# Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection

> **NCT06908096** · PHASE1 · RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 750 (estimated)

## Conditions studied

- EBV
- Epstein-Barr Virus Infection
- Infectious Mononucleosis
- Mono

## Interventions

- **BIOLOGICAL:** EBV gp350-ferritin vaccine with ALFQ adjuvant
- **BIOLOGICAL:** EBV gH/gL/gp42-ferritin nanoparticle vaccine with ALFQ adjuvant

## Key facts

- **NCT ID:** NCT06908096
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-29
- **Primary completion:** 2027-10-01
- **Final completion:** 2028-10-01
- **Target enrollment:** 750 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06908096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06908096, "Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06908096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*